Jenphar Bangladesh Limited, has stepped up in the oncology market with its new product HER-2N 200 tablet, preparation of Ribociclib Succinate 200 mg Tablet.
HER-2N is a CDK4/6 inhibitor that is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic Breast Cancer.
Ribociclib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. Thus it helps to slow down or stop the spread of cancer cells.
By launching this product, Jenphar Bangladesh Limited has enriched its Oncology portfolio, offering the treatment options in HR-positive & HER2-negative advanced Breast Cancer which will serve in a better way to the mentioned cancer patients of the country & abroad.
HER-2N, 200 mg Tab is available in a sealed HDPE container containing 21 Tablets.